Neuvotion

Executive Summary

Neuvotion is a neurotechnology company developing AI-guided brain-body interface (BBI) technologies to restore function after neurological injuries such as stroke and spinal cord injury. Founded in 2018 and based in Cambridge, MA, the company combines non-invasive body/spinal interfaces with minimally invasive brain-computer interface (BCI) technology to revolutionize neurorecovery. Despite its innovative platform, Neuvotion remains at an early stage with limited publicly available information on funding, partnerships, or clinical progress. The company's potential lies in addressing large unmet needs in neurorehabilitation, but it faces technical and regulatory hurdles common in the neurotechnology space. Given the lack of pipeline details and financial data, near-term visibility is low, though the company's focus on AI integration and dual-modality approach differentiates it from pure BCI or spinal stimulation competitors.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Extension Funding Announcement60% success
• H2 2026First-in-Human Clinical Trial Results for Stroke or SCI Indication30% success
• Q4 2026Strategic Partnership with Major Rehabilitation Hospital or Device Company40% success